Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Harefuah ; 147(6): 520-5, 574, 2008 Jun.
Artículo en Hebreo | MEDLINE | ID: mdl-18693629

RESUMEN

Adrenocortical carcinoma (ACC) is a rare cancer with a generally poor prognosis. In approximately 60% of cases the initial clinical manifestations are due to hypersecretion of adrenocortical hormones. Cushing's syndrome is the most frequent hormonal manifestation. In the remainder of the cases the tumor is identified after imaging procedures for nonspecific complaints such as abdominal pain and nausea. Medical therapy is employed in patients with unresectable or partially resected tumor and metastatic disease. The current accepted treatment is a combination of Mitotane with chemotherapy, aimed at controlling hormonal hypersecretion and reduction of tumor mass. In ACC patients there is wide variability in the course of the disease: some with metastatic disease will survive for more than 10 years, others succumb to the disease within months.


Asunto(s)
Neoplasias de la Corteza Suprarrenal/diagnóstico , Neoplasias de la Corteza Suprarrenal/tratamiento farmacológico , Neoplasias de la Corteza Suprarrenal/mortalidad , Neoplasias de la Corteza Suprarrenal/cirugía , Antineoplásicos/uso terapéutico , Síndrome de Cushing/etiología , Humanos , Náusea/etiología , Estadificación de Neoplasias , Dolor/etiología , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA